Amgen Inc. (AMGN) Guidance & Earnings Results

On 2026-08-04 Amgen Inc. reaffirmed guidance: "FY26 GAAP diluted EPS $15.80-$17.08; FY26 non-GAAP diluted EPS $22.30-$23.50; FY26 GAAP tax rate 14.5%-16.0%; FY26 non-GAAP tax rate…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

AMGNAmgen Inc.Follow AMGN — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 237.5B
P/E TTM: 27.3
Dividend yield: 2.3%
52-week: —
Next earnings: 3 Nov, in 10 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
4 Aug 26	Reaffirmed	FY26 GAAP diluted EPS $15.80-$17.08; FY26 non-GAAP diluted EPS $22.30-$23.50; FY26 GAAP tax rate 14.5%-16.0%; FY26 non-GAAP tax rate 15.0%-16.5% · full year
3 Feb 26	Mixed	Expects net selling price declines for Repatha (mid single-digits) and Prolia (accelerated erosion), and continued RAVICTI erosion · full year
5 Aug 25	Reaffirmed	FY25 GAAP diluted EPS $10.97-$12.11; Non-GAAP diluted EPS $20.20-$21.30; GAAP tax rate 11.0%-12.5%; Non-GAAP tax rate 14.5%-16.0% · full year

Amgen Inc. — questions

What guidance did Amgen Inc. give?: On 2026-08-04: "FY26 GAAP diluted EPS $15.80-$17.08; FY26 non-GAAP diluted EPS $22.30-$23.50; FY26 GAAP tax rate 14.5%-16.0%; FY26 non-GAAP tax rate 15.0%-16.5%"
When does Amgen Inc. report earnings?: Amgen Inc.'s next earnings report is expected on 2026-11-03.

Every figure on this page comes from Amgen Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.